Autolus Therapeutics (NASDAQ:AUTL) Stock Rated Buy in New Coverage at HC Wainwright

HC Wainwright began coverage on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note published on Monday, MarketBeat reports. The firm issued a buy rating on the stock. HC Wainwright also issued estimates for Autolus Therapeutics’ Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at ($0.73) EPS and FY2030 earnings at ($0.26) EPS.

A number of other brokerages have also commented on AUTL. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Autolus Therapeutics Price Performance

NASDAQ AUTL opened at $1.38 on Monday. The business has a 50 day simple moving average of $1.85 and a 200 day simple moving average of $1.66. Autolus Therapeutics has a 52-week low of $1.18 and a 52-week high of $2.58. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. The stock has a market cap of $367.30 million, a price-to-earnings ratio of -1.30 and a beta of 2.32.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. Analysts anticipate that Autolus Therapeutics will post -0.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Privium Fund Management B.V. lifted its position in Autolus Therapeutics by 29.2% during the 3rd quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock worth $911,000 after buying an additional 106,060 shares in the last quarter. Vise Technologies Inc. bought a new position in shares of Autolus Therapeutics in the 3rd quarter valued at about $35,000. QRG Capital Management Inc. increased its position in shares of Autolus Therapeutics by 67.7% in the second quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock valued at $29,000 after acquiring an additional 7,400 shares during the last quarter. Alphabet Inc. acquired a new stake in shares of Autolus Therapeutics in the second quarter valued at about $1,117,000. Finally, Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics during the second quarter worth about $26,625,152. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Key Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Autolus announced that clinical-data abstracts will be presented at the American Society of Hematology (ASH) Annual Meeting on December 12–15. The updates could draw investor attention to its cell-therapy programs, though the announcement did not disclose the data itself. Autolus ASH clinical data announcement
• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating, offering a supportive analyst view of the stock. HC Wainwright coverage
• Negative Sentiment: HC Wainwright’s projections still show losses: it estimates a 2026 loss of $0.81 per share, versus a cited consensus loss of $0.74, and forecasts losses in later years as well. That outlook may temper optimism around the Buy rating.
• Negative Sentiment: The company granted options and restricted stock units covering a total of 204,710 shares to 15 new employees. The awards may create some shareholder dilution. Autolus inducement grants announcement

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.